Cancers & treatments·Regimen libraryAdjuvant

Dose-dense AC → T

Checked 2026-09-09

Node-positive or high-risk early breast cancer, adjuvant or neoadjuvant

Also called ddAC-T, AC-T, AC followed by T.

One cycle

every 14 days × 4 · about 8 weeks in total

14-day cycle × 4 AC then 4 paclitaxel (16 weeks) (about 8 weeks)Intravenous

Components

Drug	Dose	Route	Days	Note
Doxorubicin Cytotoxic chemotherapy (anthracycline)	60 mg/m²	IV	D1	cycles 1-4
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug)	600 mg/m²	IV	D1	cycles 1-4
Paclitaxel Cytotoxic chemotherapy (taxane)	175 mg/m² every 2 weeks × 4, or 80 mg/m² weekly × 12	IV	D1	cycles 5-8

Cycles

4 AC then 4 paclitaxel (16 weeks)

14-day cycle

Emetogenicity

High (>90%)

G-CSF

Built into the protocol

Notes

Cumulative doxorubicin 240 mg/m²; pegfilgrastim on day 2 of each AC cycle is what makes the 14-day schedule possible.
Weekly paclitaxel × 12 (ECOG E1199) is at least as effective as every-2-week dosing with less neuropathy.

Used in

Triple-negative breast cancer (TNBC)HR-positive / HER2-negative breast cancer HER2-positive breast cancer

Products

DoxorubicinCyclophosphamidePaclitaxel / nab-paclitaxel

Source

CALGB 9741, JCO 2003

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.